Eli Lilly has signed an agreement with Hims & Hers that will see its weight-loss therapies Zepbound and Foundayo sold ...

Moderna's mRNA-1469 and ChAdOx1, developed by the University of Oxford in partnership with the Serum Institute of India, ...

Rezera, formerly known as NodThera until a rebrand earlier this year, has announced the terms of its planned Nasdaq IPO, ...

For years, success in kidney disease has largely been measured by how much its progression could be slowed. Newer treatments ...

Patients with muscle-invasive bladder cancer can now receive NHS treatment with a regimen of MSD's Keytruda and Astellas' ...

T-Therapeutics and Alethio Therapeutics – have raised $133 million and $90 million, respectively, in an impressive pair of ...

While praising the breadth of its pipeline, AstraZeneca has launched a three-year cost-cutting programme that will aim to ...

Theramex, a London, UK-based specialty pharma company focusing on women's health, is changing hands in a deal reportedly ...

Novo has raised its financial guidance for 2026 on the back of rising sales of its oral weight-loss therapy Wegovy, which ...

In oncology, time is not simply a measure of care; it is a clinical variable – and increasingly a therapeutic challenge.

Hard on the heels of a £1 billion investment package by pharma companies in last week's UK Budget, AbbVie has pledged another ...

One of the things I enjoyed most about this year’s PM Society PMi Awards was the sheer breadth of the community in the room.